Strategic collaborations Acuitas is actively forming and expanding strategic partnerships with global biopharma and biotech players, including Genflow Biosciences, Circio, and RNA Technologies to advance LNP delivery and in vivo CAR-T therapies, signaling strong cross-company sales opportunities for licensing, co-development, or contract research.

Next generation LNP The company is positioned as a leader in next-generation lipid nanoparticle technology with applications across oncology vaccines, personalized CRISPR therapies, and extrahepatic targeting, offering multiple cross-sell avenues to partners seeking cutting-edge delivery solutions.

Clinical pipeline momentum With clinically validated LNPs underpinning approved products and a broad clinical trial portfolio including in-human genome editing and personalized therapies, Acuitas demonstrates continuous demand for its delivery platform, creating recurring opportunities in collaboration, licensing, and contract research for new modalities.

High profile validation Collaborations with Pfizer-BioNTech, Alnylam, and partnerships highlighted at major conferences establish prestigious credibility, creating powerful use cases for joint ventures, co-marketing, and broader partner outreach to large pharma seeking proven LNP capabilities.

Global market expansion Recent international activity and press coverage, plus a Vancouver-based hub with global partners, indicate readiness to scale partnerships across regions, presenting sales opportunities in regional licensing, technology transfer, and regional manufacturing or fulfilment collaborations.